Skip to main content

Table 1 Patient and tumor characteristics

From: Preliminary study of AI-assisted diagnosis using FDG-PET/CT for axillary lymph node metastasis in patients with breast cancer

  n %
Total patients 407  
Age mean (range) 59.2 (28–90)  
Tumor location, right/left/bilateral 228/172/7 56.0%/42.3%/1.7%
NAC, yes/no 125/282 30.7%/69.3%
Total breast cancers 414  
Type of surgery   
 Breast-conserving surgery 164 39.6%
 Modified radical mastectomy 250 61.4%
Histology   
 IDC 373 90.1%
 Others   
(Myxoid/ILC/apocrine/metaplastic) 15/14/11/1 0.9%
Molecular phenotype   
 Luminal A (ER + /HER2 − , Ki67 < 20%) 148 35.7%
 Luminal B (ER + /HER2 − , Ki67 ≥ 20%) 120 29.0%
 Luminal-HER2 (ER + /HER2 +) 43 10.4%
 HER2-positive (non-luminal) 43 10.4%
 Triple-negative 60 14.5%
Axillary lymph node metastasis   
 Present 204 49.3%
 Absent 210 50.7%
Diagnostic tool of axillary node   
 SLNB 197 47.6%
 ALND 12 2.9%
 SLNB and ALND 59 14.3%
 Aspiration cytology and ALND 60 14.5%
 Aspiration cytology and SLNB 19 4.6%
Aspiration cytology, SLNB, and ALND 67 16.2%
TNM Stage (I/II/III) 140/217/57 33.8%/52.4%/13.8%
  1. ALND: axillary lymph node dissection, ER: endocrine receptor, HER: human epidermal growth factor receptor, IDC: invasive ductal cancer, ILC: invasive lobular cancer, NAC: neoadjuvant chemotherapy, SLNB: sentinel lymph node biopsy, TNM: tumor node metastasis